{"id":"NCT01288209","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy","officialTitle":"A Phase III, Randomized, Open-label, Two-arm Trial in Japan to Investigate the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Hepatitis C, Genotype 1-Infected Subjects Who Failed to Respond to Previous IFN-based Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2011-02-02","resultsPosted":"2014-01-24","lastUpdate":"2014-01-24"},"enrollment":106,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"TMC435","otherNames":[]},{"type":"DRUG","name":"Peginterferon alfa-2a (PegIFNα-2a )","otherNames":["PEGASYS"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":["COPEGUS"]}],"arms":[{"label":"TMC435 100 mg 12 Wks + PR24/48","type":"EXPERIMENTAL"},{"label":"TMC435 100 mg 24 Wks + PR24/48","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin in genotype 1 hepatitis C virus (HCV)-infected participants who failed to respond to previous interferon (IFN)-based therapy in Japan.","primaryOutcome":{"measure":"The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)","timeFrame":"EOT (Week 24 or 48) and Week 36 or 60","effectByArm":[{"arm":"TMC435 100 mg 12 Wks + PR24/48","deltaMin":52.8,"sd":null},{"arm":"TMC435 100 mg 24 Wks + PR24/48","deltaMin":35.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":19,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":53},"commonTop":["Pyrexia","White blood cell count decreased","Anaemia","Neutrophil count decreased","Malaise"]}}